Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. / Grégoire Ruffenach; Jason Hong; Mylène Vaillancourt [and others].
Material type:
ArticleLanguage: English Publisher: [Place of publication not identified] : BMC, 2020Description: 1 online resource (1 article)Content type: - text
- computer
- online resource
Publication type: Review article.
Linked open-access copy: published version.
Open access; no subscription required for the linked open-access version. Unrestricted online access star
Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH.
Creative Commons Attribution. See the linked licence for the applicable terms.
http://creativecommons.org/licenses/by/4.0/
In English.
Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
Course allocation: B. Sc. Medical Laboratory Science.
There are no comments on this title.